Target Price | $61.20 |
Price | $61.40 |
Deviation |
0.33%
register free of charge
|
Number of Estimates | 27 |
27 Analysts have issued a price target Guardant Health, Inc. 2026 .
The average Guardant Health, Inc. target price is $61.20.
This is
0.33%
register free of charge
$73.50
19.71%
register free of charge
$20.20
67.10%
register free of charge
|
|
A rating was issued by 34 analysts: 30 Analysts recommend Guardant Health, Inc. to buy, 3 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Guardant Health, Inc. stock has an average upside potential 2026 of
0.33%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 739.02 | 911.65 |
31.04% | 23.36% | |
EBITDA Margin | -54.29% | -25.10% |
41.33% | 53.77% | |
Net Margin | -59.05% | -43.06% |
30.55% | 27.08% |
30 Analysts have issued a sales forecast Guardant Health, Inc. 2025 . The average Guardant Health, Inc. sales estimate is
This results in the following potential growth metrics:
26 Analysts have issued an Guardant Health, Inc. EBITDA forecast 2025. The average Guardant Health, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
29 Guardant Health, Inc. Analysts have issued a net profit forecast 2025. The average Guardant Health, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.56 | -3.15 |
16.82% | 11.52% | |
P/E | negative | |
EV/Sales | 8.93 |
29 Analysts have issued a Guardant Health, Inc. forecast for earnings per share. The average Guardant Health, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Guardant Health, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Raymond James |
Locked
➜
Locked
|
Locked | Jul 31 2025 |
Scotiabank |
Locked
➜
Locked
|
Locked | Jul 31 2025 |
Mizuho |
Locked
➜
Locked
|
Locked | Jun 13 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | May 06 2025 |
Scotiabank |
Locked
➜
Locked
|
Locked | May 05 2025 |
UBS |
Locked
➜
Locked
|
Locked | May 01 2025 |
Barclays |
Locked
➜
Locked
|
Locked | May 01 2025 |
Analyst Rating | Date |
---|---|
Locked
Raymond James:
Locked
➜
Locked
|
Jul 31 2025 |
Locked
Scotiabank:
Locked
➜
Locked
|
Jul 31 2025 |
Locked
Mizuho:
Locked
➜
Locked
|
Jun 13 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
May 06 2025 |
Locked
Scotiabank:
Locked
➜
Locked
|
May 05 2025 |
Locked
UBS:
Locked
➜
Locked
|
May 01 2025 |
Locked
Barclays:
Locked
➜
Locked
|
May 01 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.